Application
Western blot analysis of CEBPA Antibody (C-term) in mouse liver tissue lysates (35ug/lane). CEBPA (arrow) was detected using the purified Pab.Application
CEBPA Antibody (C-term) flow cytometric analysis of Hela cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.| Product Name | CEBPA Antibody (C-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | CEBPA; CCAAT/enhancer-binding protein alpha |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WBFC |
| WB:1:100~500 FC |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Alternative Names | CEBPA CCAAT/enhancer-binding protein alpha |
|---|---|
| Molecular Weight(MW) | 37561 Da |
| Function | C/EBP is a DNA-binding protein that recognizes two different motifs: the CCAAT homology common to many promoters and the enhanced core homology common to many enhancers |
| Tissue Specificity | This CEBPA antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 310~339 amino acids from the C-terminal region of human CEBPA. |
| Cellular Localization | Nucleus. |
| Entrez Gene | 1050 |
|---|
Application
Western blot analysis of CEBPA Antibody (C-term) in mouse liver tissue lysates (35ug/lane). CEBPA (arrow) was detected using the purified Pab.
Application
CEBPA Antibody (C-term) flow cytometric analysis of Hela cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.| Application Notes | WB:1:100~500 FC |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
